DROSPIRENONA
LIBRE DE ESTRÓGENOS
LIBRE DE RIESGOS
Monografía
IPP
A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen
Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase
Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase
MMulticenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone only pill
Estudios
Clínicos
Artículos
comentados
Anticoncepción Oral de solo Drospirenona
Estudio Multicéntrico Abierto para Evaluar en Mujeres
Estudio Multicéntrico Prospectivo a un Año. Abierto, de un Solo Brazo
